Stock Market Reviews

OPK (OPKO Health, Inc.) News

Get the latest news, insights, and market updates on OPK (OPKO Health, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
  First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced the initiation and recent dosing of the first patient in a Phase 1/2a clinical trial (NCT07110584) with MDX2004, a first-in-class trispecific antibody-fusion protein for oncology a
  Oct 28, 2025 - $OPK
• Here's Why You Should Add OPKO Health Stock to Your Portfolio
  OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.
  Oct 23, 2025 - $OPK
• OPKO Health to Report Third Quarter 2025 Financial Results on October 29
  MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, October 29, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on October 29th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION O
  Oct 22, 2025 - $OPK
• OPKO Health, Inc. (OPK)’s ModeX Division Pushes Four Immuno-Oncology Candidates into Phase 1
  We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. OPKO Health, Inc. is one of them. OPKO Health, Inc. (NASDAQ:OPK) is a diversified healthcare company with operations spanning diagnostics, pharmaceuticals, and innovative therapies. Its business is anchored by BioReference Laboratories and a growing pipeline focused on immuno-oncology, immune rejuvenation, […]
  Oct 1, 2025 - $OPK
• 44% of OPKO Health, Inc. (NASDAQ:OPK) is owned by insiders, and they've been buying recently
  Key Insights OPKO Health's significant insider ownership suggests inherent interests in company's expansion A total of...
  Sep 23, 2025 - $OPK
• Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
  ENTX posts positive PK data for its first oral GLP-2 therapy, signaling a potential breakthrough in short bowel syndrome treatment.
  Sep 18, 2025 - $OPK